Patient-derived tumour xenograft models encyclopedia

Researchers from the Novartis Institutes for BioMedical Research established 1,075 patient-derived tumour xenograft models (PDXs) with a diverse set of driver mutations. With these PDXs, they performed in vivo compound screens to assess the population responses to 62 treatments across six indications. They demonstrated both the reproducibility and the clinical translatability of this approach by identifying associations between a genotype and drug response, and established mechanisms of resistance. Read more here.